245 related articles for article (PubMed ID: 24554304)
21. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
[TBL] [Abstract][Full Text] [Related]
22. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
[TBL] [Abstract][Full Text] [Related]
23. Nontransfusional approach to increased platelet count in patients with cirrhosis and thrombocytopenia.
Tripodi A; Primignani M
Hepatology; 2013 Sep; 58(3):1177-80. PubMed ID: 23703879
[No Abstract] [Full Text] [Related]
24. Eltrombopag in chronic hepatitis C.
Mihăilă RG; Cipăian RC
World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
[TBL] [Abstract][Full Text] [Related]
25. Eltrombopag in thrombocytopenia.
Zimmer J; Hentges F; Andrès E
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
[No Abstract] [Full Text] [Related]
26. Current status of thrombopoietic agents.
Rhodes E; Stasi R
Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
[TBL] [Abstract][Full Text] [Related]
27. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
Li W; Morrone K; Kambhampati S; Will B; Steidl U; Verma A
Leukemia; 2016 Mar; 30(3):536-44. PubMed ID: 26500138
[TBL] [Abstract][Full Text] [Related]
28. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
[TBL] [Abstract][Full Text] [Related]
29. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
Pathak S; Roth M; Verma A; Steidl U
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1667-75. PubMed ID: 24215532
[TBL] [Abstract][Full Text] [Related]
30. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
[TBL] [Abstract][Full Text] [Related]
31. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience.
Yaman Y; Elli M; Şahin Ş; Özdilli K; Bilgen H; Bayram N; Nepesov S; Anak S
Pediatr Transplant; 2021 Aug; 25(5):e13962. PubMed ID: 33452850
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children.
Ali S; Gassas A; Kirby-Allen M; Krueger J; Ali M; Schechter T
Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28653480
[TBL] [Abstract][Full Text] [Related]
33. Eltrombopag for the treatment of immune thrombocytopenia.
Cheng G
Expert Rev Hematol; 2011 Jun; 4(3):261-9. PubMed ID: 21671710
[TBL] [Abstract][Full Text] [Related]
34. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
[No Abstract] [Full Text] [Related]
35. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
[TBL] [Abstract][Full Text] [Related]
36. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
37. [Eltrombopag for refractory thrombocytopenia in patients with allogeneic hematopoietic stem cell transplantation].
Ma YR; Huang XJ; Mo XD; Han W; Yan CH; Chen Y; Ji Y; Chen YY; Wang Y; Zhang XH; Liu KY; Xu LP
Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1065-1069. PubMed ID: 28088971
[TBL] [Abstract][Full Text] [Related]
38. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
Waisbren J; Dinner S; Altman J; Frankfurt O; Helenowski I; Gao J; McMahon BJ; Stein BL
Int J Hematol; 2017 Jan; 105(1):44-51. PubMed ID: 27558575
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).
Cela I; Miller IJ; Katz RS; Rizman A; Shammo JM
Clin Adv Hematol Oncol; 2010 Nov; 8(11):806-9. PubMed ID: 21326158
[No Abstract] [Full Text] [Related]
40. Eltrombopag in patients with chronic liver disease.
Giannini EG; Afdhal NH
Expert Opin Pharmacother; 2013 Apr; 14(5):669-78. PubMed ID: 23452139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]